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Abstract
 
Although considerable evidence implicates the cytokine interferon (IFN)-
 
 
 
 in atherogenesis,
the proximal inducers and the range of sources of its expression remain unknown. This study
tested the hypothesis that interleukin (IL)-18 regulates IFN-
 
 
 
 expression during atherogenesis.
Indeed, human atheroma in situ expressed IL-18 and elevated levels of its receptor subunits,
IL-18R
 
 
 
/
 
 
 
, compared with nondiseased arterial tissue. IL-18 occurred predominantly as the
mature, 18-kD form and colocalized with mononuclear phagocytes (MØ), while endothelial
cells (ECs), smooth muscle cells (SMCs), and MØ all expressed IL-18R
 
 
 
/
 
 
 
. Correspondingly
in vitro, only MØ expressed IL-18, while all three cell types displayed the IL-18R
 
 
 
/
 
 
 
 com-
plex constitutively, exhibiting enhanced expression upon stimulation with LPS, IL-1
 
 
 
, or tu-
mor necrosis factor (TNF)-
 
 
 
. IL-18 signaling evoked effectors involved in atherogenesis, e.g.,
cytokines (IL-6), chemokines (IL-8), intracellular adhesion molecules (ICAM)-1, and matrix
metalloproteinases (MMP-1/-9/-13), demonstrating functionality of the receptor on ECs,
 
SMCs, and MØ. Finally, IL-18, particularly in combination with IL-12, induced the expression
 
of IFN-
 
 
 
 in cultured MØ and, surprisingly, in SMCs (but not in ECs). The expression of func-
tional IL-18 and IL-18 receptor on human atheroma-associated ECs, SMCs, and MØ, and its
 
unexpected ability to induce IFN-
 
 
 
 expression in SMCs, suggests a novel paracrine proin-
flammatory pathway operating during atherogenesis.
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Introduction
 
Recent evidence accords a prominent role of pathways of
innate and acquired immunity in the pathogenesis of ath-
erosclerosis (1, 2). Cytokines have garnered considerable
interest as potential mediators of this process (1–3). In par-
ticular, recent in vitro and in vivo studies demonstrated
that the cytokine IFN-
 
 
 
 can promote atherosclerosis (4–7).
However, the proximal inducers as well as the spectrum of
cell types capable of expressing this pleiotropic cytokine
have remained poorly understood. Originally, expression
of IFN-
 
 
 
 was considered restricted to T lymphocytes and
NK cells (8, 9). However, previous reports suggest a
broader panel of cell types as the source of this potent im-
munomodulator, including B cell and certain tumor cell
 
lines (10, 11). Moreover, mononuclear phagocytes (MØ)
 
*
 
,
a cell type central to atherogenesis, may elaborate IFN-
 
 
 
,
although these findings have aroused controversy (12, 13).
In addition to antigenic stimulation, proposed inducers
of IFN-
 
 
 
 expression in T lymphocytes within atheroma in-
 
clude proinflammatory cytokines, such as IL-1
 
 
 
 and TNF-
 
 
 
,
microbial components, such as endotoxin (LPS), as well as
 
This work was presented in part at the Scientific Sessions of the American
Heart Association, New Orleans on November 12–15, 2000, and pub-
 
lished in abstract form (
 
Circulation
 
. 2000. 18:11–66). Further parts of this
work were presented at the 11th International Congress of Immunology,
Stockholm, Sweden, July 22–27, 2001, and published in abstract form
(
 
Scand. J. Immunol.
 
 2001. 54:A5).
Address correspondence to Uwe Schönbeck, Cardiovascular Medicine,
Brigham and Women’s Hospital, Harvard Medical School, 221 Long-
wood Ave., LMRC 307, Boston, MA 02115. Phone: 617-278-0455;
Fax: 617-732-6961; E-mail: uschoenbeck@rics.bwh.harvard.edu
 
*
 
Abbreviations used in this paper:
 
 EC, endothelial cell; ICAM, intracellular
adhesion molecule; MMP, matrix metalloproteinase;
 
 
 
MØ, mononuclear
phagocytes; SMC, smooth muscle cell. 
246
 
IL-18/IL-18R in Human Atheroma
 
IFN-
 
 
 
 itself, probably via paracrine and/or autocrine path-
ways (8–10, 12). Of note, recent studies identified IL-18, a
member of the IL-1 cytokine family, as a potent IFN-
 
 
 
–
inducing factor, originally termed IGIF (14–16). Initially
identified in Kupffer cells and MØ (14) IL-18 is further ex-
pressed by osteoblasts (17), chondrocytes (18), and epider-
mal keratinocytes (19). Proinflammatory cytokines includ-
ing IL-1
 
 
 
, TNF-
 
 
 
, or IL-6, as well as LPS, induce IL-18
gene expression (20, 21), directing the synthesis of an inac-
tive 24-kD precursor. Similar to its analogue IL-1
 
 
 
, bio-
logical activity of IL-18 requires processing of the zymogen
by the IL-1
 
 
 
–converting enzyme, caspase-1, to the 18-kD
mature form (22, 23). Although IL-18 induces IFN-
 
 
 
 ex-
pression in T lymphocytes, synergism with IL-12 markedly
enhances this function (14, 24). Consistent with a key role
for mature IL-18 in the regulation of IFN-
 
 
 
 synthesis, IL-
18–, or caspase-1–deficient mice showed a markedly di-
minished expression of IFN-
 
 
 
 (25, 26). Beyond induction
of the central proatherogenic factor IFN-
 
 
 
 (4–6, 27, 28),
IL-18 also augments the production of various other medi-
ators implicated in atherogenesis, such as the proinflamma-
tory cytokines IL-1
 
 
 
, IL-6, or TNF-
 
 
 
; the chemokines IL-8,
MCP-1, and MIP-1
 
 
 
; the intracellular adhesion mole-
cule (ICAM)-1; the growth factor GM-CSF; inducible ni-
tric oxide synthase (the high capacity isoform); or inducible
cyclooxygenase (Cox-2) (15, 16, 18, 20, 21, 24, 29). Fur-
thermore, IL-18 promotes Th1 responses (24, 25, 30, 31),
which dominate during human atherogenesis (3). Notably,
the Th1 lymphocyte subpopulation, but not Th2 lympho-
cytes, express the receptor for IL-18 (30). IL-18 acts by
binding to the heterodimeric IL-18 receptor complex,
comprised of the IL-1 receptor-related protein (IL-1Rrp),
termed IL-18R
 
 
 
, and the IL-1 receptor accessory protein-
like (IL-1RacPL), termed IL-18R
 
 
 
 (32–34). While IL-
18R
 
 
 
 represents the ligand-binding chain, IL-18R
 
 
 
 ap-
pears to assist in the formation of a high affinity complex
and mediates intracellular signals (20). Inflammatory cyto-
kines overexpressed in human atheroma, such as IL-1
 
 
 
,
TNF-
 
 
 
, and IL-12 (2, 35), enhance the expression of both
receptor chains on NK cells and T lymphocytes, thereby
increasing their responsiveness to IL-18 (20). IL-18–medi-
ated processes may contribute to chronic inflammatory dis-
orders such as rheumatoid arthritis (36, 37). Yet the expres-
sion and function of this cytokine and its receptor within
human atherosclerotic lesions or atheroma-associated cells
types remained poorly understood. We report here overex-
pression of both IL-18 and IL-18R
 
 
 
/
 
 
 
 within human
atheroma in situ compared with nondiseased arterial tissue,
and demonstrate that ligation of the receptor on cultured
endothelial cells (ECs), smooth muscle cells (SMCs), and
MØ triggers atheroma-associated processes in vitro, includ-
ing the unexpected finding that human vascular SMCs
themselves can express IFN-
 
 
 
 in response to IL-18.
 
Materials and Methods
 
Materials.
 
Human recombinant mature IL-1
 
 
 
, TNF-
 
 
 
, and
IFN-
 
 
 
 were obtained from Endogen. Human recombinant ma-
 
ture IL-12 and IL-18 were purchased from R&D Systems. 
 
Esch-
erichia coli
 
 endotoxin (LPS) and Polymyxin B were provided by
Sigma-Aldrich. 
 
Cell Isolation and Culture.
 
Cultured human vascular ECs and
SMCs were isolated from saphenous veins by collagenase treat-
ment and explant outgrowth, respectively, and used through pas-
sage 3, as described previously (38, 39). MØ were isolated from
freshly prepared leukocyte concentrates by density gradient cen-
trifugation using Lymphocyte Separation Medium (Organon-
Teknika) and subsequent adherence to plastic culture flasks. MØ
were cultured for 10 d in RPMI 1640 containing 2% human se-
rum (Sigma-Aldrich; as described previously in references 38 and
39). All three cell types were cultured before (24 h) and during
the experiment in media lacking FBS-serum; ECs in M199 sup-
plemented with 0.1% bovine serum albumin, SMCs in IT (Insu-
lin/Transferrin) medium, and MØ in RPMI 1640 lacking serum
(38, 39). The purity of monocytes/MØ was 
 
 
 
92%, as deter-
mined by FACS
 
®
 
 analysis (anti–human CD68 mAb FITC; BD
PharMingen). Culture media and FBS contained 
 
 
 
40 pg endo-
toxin/ml as determined by the chromogenic Limulus amoebo-
cyte assay (QLC-1000; BioWhittaker).
 
RT-PCR.
 
Total RNA isolated from cultures of ECs, SMCs,
or MØ using RNazol (Tel-Test) was assessed for purity and yield
spectrophotometrically (2100 Bioanalyzer; Agilent Technolo-
gies), was DNase-treated (DNase I, 15 min, 25
 
 
 
C; Life Technol-
ogies), and was finally reverse transcribed (2 
 
 
 
g total RNA, 50
min, 42
 
 
 
C) in 20 
 
 
 
l total reaction mix (200 U Superscript II Re-
verse Transcriptase; 25 
 
 
 
g/ml Oligo [dT]
 
12–18
 
 primers; 10 mM
DTT; 0.5 mM dNTPs; 4 
 
 
 
l First Strand Buffer; all final concen-
trations; all Life Technologies). RT reaction products (2 
 
 
 
l) were
mixed with either the IL-18R
 
 
 
 (sense: 5
 
 
 
-CTTCACATTCT-
TGCCCCAAT-3
 
 
 
; antisense: 5
 
 
 
-GCAGCTGCATCCAGT-
TATGA-3
 
 
 
), IL-18R
 
 
 
 (sense: 5
 
 
 
-GAAGAACACTTGGCCCT-
GAG-3
 
 
 
; antisense: 5
 
 
 
-TTTCACAGGCATGTGGTAGC-3
 
 
 
),
or IFN-
 
 
 
 (sense: 5
 
 
 
-TTTAGCTCTGCATCGTTTTG-3
 
 
 
; anti-
sense: 5
 
 
 
-CATGTATTGCTTTGCGTTGG-3
 
 
 
) primer pair (0.2
 
 
 
M each) in 50 
 
 
 
l total reaction mix (1.5 mM MgCl
 
2
 
, 0.2 mM
dNTPs, 2.5 U Platinum 
 
Taq
 
 DNA Polymerase, and 5 
 
 
 
l 10
 
 
 
PCR buffer; all Life Technologies). The PCR reaction mix was
applied to (i) 35 cycles at 94
 
 
 
C (60 s), 60
 
 
 
C (60 s), and 72
 
 
 
C (90
s) for IL-18R
 
 
 
 and IFN-
 
 
 
, or (ii) 40 cycles at 94
 
 
 
C (60 s), 55
 
 
 
C
(60 s), and 72
 
 
 
C (90 s) for IL-18R
 
 
 
. Aliquots (10 
 
 
 
l) of the PCR
products were run on 1.5% agarose gels and visualized by UV-
transillumination. The expected size for the RT-PCR product
was 450 bp for IL-18R
 
 
 
, 399 bp for IL-18R
 
 
 
, and 375 bp for
IFN-
 
 
 
. Loading of equal amounts of template was verified by
RT-PCR for GAPDH yielding similar band intensities for all
samples (data not shown). Mock RT reaction products, obtained
in the absence of reverse transcriptase, or H
 
2
 
O served as templates
for negative control studies (data not shown).
 
Western Blot Analysis.
 
To extract proteins, tissue of nonath-
erosclerotic (
 
n 
 
  
 
5) and atheromatous human carotids and aorta
(
 
n 
 
  
 
7) as well as abdominal aortic aneurysm (
 
n 
 
  
 
3) were snap
frozen and homogenized under liquid nitrogen using mortar and
piston. Pulverized specimens were incubated with ice-cold lysis
buffer (0.3 g tissue/ml lysis buffer: 10 mM NaH
 
2
 
PO
 
4
 
, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate,
0.2% NaN
 
3
 
, 5 mM EDTA, 20 
 
 
 
g/ml soybean trypsin inhibitor,
0.1 mM PMSF, 1 
 
 
 
g/ml aprotinin, and 1 
 
 
 
g/ml leupeptin). Tis-
sue extracts as well as cell extracts (both 50 
 
 
 
g total protein per
lane) and supernatants of cultured ECs, SMCs, and MØ were
separated by SDS-PAGE and applied to Western blot analysis as
described previously (38, 39), using the respective primary (goat 
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anti–human IL-18 (0.2 
 
 
 
g/ml; R&D Systems); goat anti–human
IL-18R
 
 
 
 (1 
 
 
 
g/ml; R&D Systems); mouse anti–human IL-12
 
p40
 
(1 
 
 
 
g/ml; Genzyme); mouse anti–human IL-1
 
 
 
 (1 
 
 
 
g/ml; Up-
state Biotechnologies); rabbit anti–human Caspase-1
 
p20
 
 (Santa
Cruz Biotechnology, Inc.; 0.2 
 
 
 
g/ml); all final concentration)
and secondary antibody. Immunoreactive proteins were visual-
ized using the Western blot chemiluminescence system
(NEN™). To test antibody specificity, Western blots were de-
veloped with antibodies preincubated (2 h, 37
 
 
 
C) with the re-
spective recombinant protein (5 
 
 
 
g/ml IL-18 or IL-18R
 
 
 
; R&D
Systems). Moreover, results were validated in additional experi-
ments using antibodies of different origin (rabbit anti–human IL-
18 (1 
 
 
 
g/ml; Serotec); mouse anti–human IL-18R
 
 
 
 (1 
 
 
 
g/ml;
R&D Systems). Loading of equal amounts of protein was verified
by subsequent staining of these blots with Coomassie blue as well
as redeveloping blots with an mouse anti–human GAPDH anti-
body (1 
 
 
 
g/ml; Biodesign) (data not shown). Densitometric
analysis of digital images of the respective Western blots em-
ployed ImagePro software (Media Cybernetics).
 
ELISA.
 
Supernatants of cultured ECs, SMCs, or MØ were
added (2 h) to 96-well modules coated with capturing mono-
clonal mouse anti–human IL-6, IL-8, or IFN-
 
 
 
 antibody (1 
 
 
 
g/
ml, 4
 
 
 
C, overnight) and blocked with PBS/2% BSA (2 h, RT).
Plates were washed (PBS/0.1% Tween 20) three times and the
respective biotin-labeled antibody (0.5 
 
 
 
g/ml) was added (1 h).
Finally, wells were incubated for 30 min with alkaline phos-
phatase (Vectastain ABC kit, AK-500; Vector Laboratories), and
were washed four times. Antibody binding was visualized by add-
ing 
 
p
 
-nitrophenyl phosphate (1.39 mg/ml; Sigma-Aldrich), and
absorbance determined at 405 nm. Cytokine concentrations were
calculated using a standard curve prepared with the respective re-
combinant cytokine. Samples were assayed in triplicates. Error
bars represent standard deviation.
 
Flow Cytometry.
 
Confluent cultures of human vascular ECs,
SMCs, or MØ were washed with ice-cold PBS, harvested by
trypsinization, fixed (PBS/4% paraformaldehyde, 15 min), and
subsequently washed once with PBS/0.2% BSA before being in-
cubated (1 h, 4
 
 
 
C) with either buffer alone, PE-conjugated con-
trol IgG, PE-conjugated mouse anti–human IL-18R
 
 
 
 antibody
(4 
 
 
 
g/ml; R&D Systems), or mouse anti–human ICAM-1 anti-
body (10 
 
 
 
g/ml; provided by M.A. Gimbrone, Jr., Brigham and
Women’s Hospital, Boston, MA) followed by PE-conjugated
rabbit anti–mouse antibody (20 
 
 
 
g/ml). To determine activity of
the IFN-
 
 
 
 released by SMCs, supernatants of SMC cultures (1:2
diluted in M199) were applied (48 h) in absence or presence of
neutralizing mouse anti–human IFN-
 
 
 
 antibody (5 
 
 
 
g/ml; R&D
Systems) to confluent EC cultures. ECs were processed as de-
scribed above and incubated with PE-conjugated control IgG or
mouse anti–human MHC II antibody (1 h, 4
 
 
 
C; Beckman
Coulter). Subsequently, cells were washed with PBS/0.2% BSA
and analyzed in a Becton Dickinson FACScan™ flow cytometer
using CELLQuest™
 
 
 
software (Becton Dickinson). At least 20,000
viable cells per condition were analyzed.
 
Immunohistochemistry.
 
5-
 
 
 
m serial cryostat sections of surgical
specimens of human carotid atheroma (
 
n 
 
  
 
3), normal carotids
from autopsies, and nondiseased aorta from cardiac transplanta-
tion donors (
 
n 
 
  
 
3) were cut, air-dried onto microscope slides,
fixed in acetone (
 
 
 
20
 
 
 
C, 5 min), and preincubated with PBS
containing 0.3% hydrogen peroxide. Subsequently, sections were
incubated (30 min) with primary mouse anti–human IL-18 (0.25
 
 
 
g/ml, final concentration), goat anti–human IL-18R
 
 
 
 (3 
 
 
 
g/
ml, final concentration; both R&D Systems), mouse anti–human
muscle actin mAb for SMCs (1:35; Enzo Diagnostics), mouse-
 
anti-human CD31 mAb for EC (1: 35; Dako), mouse anti–
human CD68 for MØ (1:500; Dako), mouse anti–human CD3
for T cells (1:25; Dako), or control antibody (0.25 
 
 
 
g/ml mouse
myeloma protein MOPC-21 or 3 
 
 
 
g/ml goat IgG, both final
concentration; both Sigma-Aldrich), diluted in PBS supple-
mented with 5% appropriate serum, and processed according to
the recommendations provided by the supplier (Universal Dako
LSAB kit; Dako). For control purposes staining was validated in
additional experiments using goat anti–human IL-18 (5 
 
 
 
g/ml)
and mouse anti–human IL-18R
 
 
 
 (1.5 
 
 
 
g/ml, both final con-
centration; both R&D Systems). For colocalization with the re-
spective cell type by immunofluorescence double labeling, goat
anti–human IL-18 or IL-18R
 
 
 
 antibody was applied for 90 min
followed by biotinylated secondary antibody (45 min) and Texas
red-conjugated streptavidin (20 min; Amersham Pharmacia Bio-
tech). Subsequent to application of the avidin/biotin blocking kit
(Vector Laboratories), anti-muscle actin mAb for SMCs (1:35;
Enzo Diagnostics), anti-CD31 mAb for EC (1:35; Dako), or
anti-CD68 mAb for MØ (1:500; Dako) were added (overnight,
4
 
 
 
C). Finally, the appropriate secondary antibodies were applied
for 45 min followed by streptavidin-FITC (Amersham Pharmacia
Biotech) for 20 min.
 
In Situ Hybridization.
 
In situ hybridization was performed
accordingly to the instructions of the manufacturer (Innogenex).
Briefly, frozen tissue sections as well as cultures of ECs, SMCs,
and MØ on four-chamber slides were fixed in cold acetone, air-
dried, and incubated (10 min, 65
 
 
 
C; subsequently for 2 h at
37
 
 
 
C) with a mixture of FITC-labeled IL-18R
 
 
 
 (5
 
 
 
-CCC-
GTGTTCCTGTCATCACTCCAATAACTTCATTCCTTTG-
3
 
 
 
; 5
 
 
 
-TGCAACAAGCCAAAGAAATATCCAGCCCAAAC-
AGAGCATT-3
 
 
 
; 5
 
 
 
-GCCCTGGTGATAGTCATAAACTTC-
ATCCACTACGATTCGG-3
 
 
 
; 5
 
 
 
-CTCTGGTAGGTCCGG-
TACAGCAGCACTATTTCAATCCAGT-3
 
 
 
), and IFN-
 
 
 
 (5
 
 
 
-
CATCGTTTCCGAGAGAATTAAGCCAAAGAAGTTGA-
AATCA-3
 
 
 
; 5
 
 
 
-AAGAGAACCCAAAACGATGCAGAGCT-
GAAAAGCCAAGATA-3
 
 
 
; 5
 
 
 
-TTTTCTGTCACTCTCCTC-
TTTCCAATTCTTCAAAATGCCT-3
 
 
 
) antisense oligomers,
or the respective sense (control) oligomers (all 4 
 
 
 
g/ml, final
concentration) in hybridization-buffer. Finally, slides were
washed three times, incubated with biotinylated mouse anti-
FITC antibody (1 h), followed by alkaline phosphatase-conju-
gated streptavidin (30 min) and NBT/BCIP chromogen solu-
tion (1 h). Adjacent sections were analyzed for SMCs, MØ,
and T cell content by immunohistochemistry as described
above.
 
 Statistical Analysis.
 
Data are presented as mean 
 
 
 
 SD and
groups were compared using the Student’s t test. A value of P  
0.05 was considered significant.
Results
Human Atherosclerotic Lesions Express IL-18 and IL-18 Re-
ceptor (IL-18R / ) In Situ. Non-diseased arterial tissue
lacked immunoreactive IL-18, but showed basal expression
of IL-18R  (Fig. 1). In contrast, human atheroma stained
strongly for IL-18 and showed enhanced staining for IL-
18R , compared with nonatherosclerotic tissue. Control
IgG showed no signal. Evaluation of IL-18R  expression,
using in situ hybridization since antibodies were not avail-
able, demonstrated faint basal expression of IL-18R  tran-
scripts in nondiseased tissue, which was markedly enhanced248 IL-18/IL-18R in Human Atheroma
in atherosclerotic lesions (Fig. 1). Controls using the re-
spective sense probe did not yield a specific signal.
In accord with these studies, immunofluorescence dou-
ble-labeling demonstrated that IL-18 localized with le-
sional MØ, rather than SMCs or ECs, whereas IL-18R 
colocalized with all three atheroma-associated cell types
(Fig. 2). Moreover, extracts of atheromatous tissue, but
not of nondiseased arterial tissue, contained immunoreac-
tive IL-18 (Fig. 3 A). All plaques analyzed (n   7) con-
tained immunoreactive 24-kD and 18-kD proteins, corre-
sponding to the predicted molecular weight for precursor
and mature IL-18. Typically the 18-kD form predomi-
nated in Western blot analysis. Of note, protein extracts
obtained from abdominal aortic aneurysm specimens re-
vealed expression of predominantly the 24-kD precursor
form (Fig. 3 B), suggesting that the protein extraction pro-
Figure 1. Human atherosclerotic lesions express IL-18, IL-18R , and IL-18R . Serial cryostat sections of frozen specimens of nonatherosclerotic
aorta (Normal) and carotid atheroma (Atheroma) were analyzed by either immunohistochemistry, using mouse anti–human IL-18 (top panels) or goat
anti–human IL-18R  antibodies (middle column), or by in situ hybridization, using IL-18R  antisense oligomers (right column). The corresponding
lower panels as well as insets depict higher magnifications (40 ) of the overviews (4 ) presented in the top panels. Control experiments (bottom panels)
demonstrated that application of MOPC-21, goat IgG (data not shown), or IL-18R  sense oligomers did not yield specific staining in atherosclerotic
specimens. The asterisks indicate the lumen of the vessels. Analysis of tissue obtained from two other nonatherosclerotic as well as atherosclerotic speci-
mens showed similar results.249 Gerdes et al.
cedure employed did not cause artifactual, postharvesting
degradation of precursor IL-18, and did not account for
the 18-kD band in atherosclerotic tissue. Parallel addition
of recombinant human IL-1  precursor, the other sub-
strate of caspase-1, to protein extracts from atherosclerotic
tissue yielded recovery of the 33-kD precursor, but not
smaller forms (Fig. 3 B), a further indication that posthoc
proteolysis did not explain the abundance of mature IL-18
Figure 2. Differential expression of IL-18 and IL-18R  in ECs, SMCs, and MØ in human atherosclerotic lesions. Double-immunofluorescence stain-
ing colocalized IL-18 (red, left) or IL-18R  (red, right) with ECs (anti-CD31), SMCs (anti- -actin), or MØ (anti-CD68) within atherosclerotic plaques.
Analysis of three atheroma from different individuals showed similar results.
Figure 3. Human atherosclerotic lesions contain immunoreactive IL-18 and IL-18R . (A) Extracts (50  g/lane) of nonatherosclerotic arterial speci-
mens (Normal) as well as atherosclerotic lesions (Atheroma) were applied to SDS-PAGE and subsequent Western blot analysis using either an anti–IL-18,
anti–IL-18R , anti–caspase-1P20, or anti–IL-12P40 antibody. (B) As control for protein degradation, (top) protein extracts of abdominal aortic aneurysm
(AAA) were applied to Western blot analysis for IL-18 or (bottom) exogenous recombinant IL-1  precursor (300 ng/mg tissue) was added to extracts of
atherosclerotic tissue. The positions of the molecular weight markers are indicated on the left. Analysis of tissue obtained from a total of five nonathero-
sclerotic as well as seven atherosclerotic specimens showed similar results.250 IL-18/IL-18R in Human Atheroma
in plaques. Human atheroma furthermore contained sig-
nificantly higher concentrations of IL-18R  compared
with nondiseased tissue (8.9   1.7-fold; n   7; P   0.005)
(Fig. 3 A). Preincubation (2 h) of the anti–IL-18 or anti–
IL-18R  antibody with the respective recombinant
protein markedly diminished immunoreactive bands in
Western blots, supporting specificity of the antibodies em-
ployed (data not shown). Furthermore, IL-18 and IL-
18R  antibodies of different origin (rabbit anti–human
IL-18 and mouse anti–IL-18R , respectively) yielded sim-
ilar data (data not shown). In view of the involvement of
caspase-1 in the processing of IL-18 (22, 23) and the re-
ported synergism of IL-18 with IL-12 (14, 24), we further
analyzed atherosclerotic tissue extracts for the expression
of caspase-1 and IL-12. In agreement with previous im-
munohistochemical analysis (40, 41), atherosclerotic but
not nondiseased arterial tissue contained the active p20
subunit of Caspase-1 (Fig. 3 A), consistent with the pres-
ence of processed, mature IL-18. Moreover, atheroscle-
rotic but not nondiseased specimens expressed IL-12p40
(Fig. 3 A), in accord with the previously reported tran-
scriptional regulation (35).
Differential Expression of IL-18 and IL-18 Receptor (IL-
18R / ) in Human Vascular ECs, SMCs, and MØ In
Vitro. Further studies tested the hypothesis that ather-
oma-associated mediators regulate expression of IL-18 and
its receptor in ECs, SMCs, and MØ. In accord with the in
situ observation of the MØ-restricted expression of IL-18
in atheroma, we did not detect immunoreactive ligand in
either unstimulated, IL-1 –, or TNF- –stimulated ECs or
SMCs in vitro (Fig. 4). However, in agreement with pre-
vious reports (20, 31), these proinflammatory cytokines as
well as endotoxin induced expression and release of IL-18
by MØ, detected by Western blotting as a 24-kD and 18-
kD immunoreactive protein, corresponding to the pre-
dicted molecular weight for the precursor and mature
form, respectively. In contrast to the ligand, all three cell
types showed basal IL-18R  expression that rose after
stimulation with IL-1  or TNF-  (Fig. 4). FACS® analysis
revealed surface expression of IL-18R  on these vascular
wall cells (Fig. 5), which was enhanced after stimulation
with IL-1  or TNF- . Interestingly, IFN-  employed as a
sole stimulus did not enhance expression of IL-18R ,
whereas in combination with IL-1  or TNF-  it evoked
more IL-18R  cell surface expression on ECs and SMCs
than the other stimuli tested. Combinations of cytokines
present in atheroma, elicited IL-18R  expression on ECs
and SMCs time- (Fig. 5) and concentration- (data not
shown) dependent, requiring a minimum of 12-h stimula-
tion with 0.1 ng IL-1 /0.5 ng TNF- /10 U IFN- /ml.
Maximal expression occurred after 48 h of stimulation
with 10 ng IL-1 /50 ng TNF- /1,000 U IFN- /ml and
did not increase after more prolonged incubation (96 h;
data not shown). Analysis of the expression of the second
component of the IL-18 receptor complex, IL-18R , em-
ployed RT-PCR, since antibodies were not available.
Amplification of cDNA prepared from cultures of unstim-
ulated ECs, SMCs, or MØ demonstrated constitutive ex-
pression of IL-18R  transcripts (Fig. 6). In accordance
with the data obtained regarding the regulation of IL-
Figure 4. Differential expres-
sion of IL-18 and IL-18R  on
cultured ECs, SMCs, and MØ in
vitro. Supernatants (50  l/lane;
for IL-18) or lysates (50  g total
protein/lane; for IL-18R ) of
ECs, SMCs, or MØ cultures, in-
cubated for 24 h with serum-free
medium alone (None) or human
recombinant IL-1  (10 ng/ml),
TNF-  (50 ng/ml), combina-
tions thereof, or LPS (100 ng/
ml) were analyzed by Western
blotting using anti–human IL-18
(left) or IL-18R  (right) anti-
body. The positions of the mo-
lecular weight markers are indi-
cated on the left. Three
independent experiments yielded
similar data.251 Gerdes et al.
Figure 5. Proinflammatory cytokines induce the cell surface expression of IL-18R  in human ECs and SMCs. Human vascular SMCs and ECs were incu-
bated 36 h (stimuli) or for the respective times (time dependency) with either medium alone (None) or medium supplemented with IL-1  (10 ng/ml), IFN- 
(1,000 U/ml), TNF-  (50 ng/ml), or combinations thereof, and were studied for the expression of IL-18R  by FACS® analysis. Staining for IL-18R  (solid
histograms) is compared with the isotype control (dotted line) and unstained control (solid line). At least 20,000 viable cells were analyzed for each staining. Val-
ues of geometric mean fluorescence are indicated in each panel. Similar results were obtained in three independent experiments using cells of different donors.
Figure 6. Proinflammatory cytokines induce the expression of IL-18R  and IL-18R  transcripts in human ECs, SMCs, and MØ. Expression of
IL-18R  and IL-18R  transcripts was analyzed by RT-PCR using RNA obtained from ECs, SMCs, and MØ cultured in medium alone (None), or
medium supplemented with TNF-  (50 ng/ml), endotoxin (100 ng/ml LPS), 50  g/ml IL-12, 10  g/ml IL-18, or a combination of the latter two.
PCR products were applied to 1.5% agarose gels. Positions of the base pair markers are indicated on the left. Comparable data were obtained using cells
from at least three different donors.252 IL-18/IL-18R in Human Atheroma
18R  protein expression, stimulation with proinflamma-
tory cytokines, such as IL-1  (data not shown) or TNF- ,
but also IL-18 itself, enhanced the detectable band intensi-
ties for both IL-18R  and IL-18R  transcripts in ECs and
SMCs. Although RT-PCR studies do not allow for quan-
titative analysis, these studies suggest that the expression of
both IL-18 receptor subunits may be regulated similarly.
The IL-18 Receptor Expressed on Human Vascular ECs and
SMCs Is Functional. To test the functionality of the IL-18
receptor complex expressed on ECs and SMCs we incu-
bated either cell type with recombinant IL-18. Stimulation
with the ligand indeed induced the expression of the
proinflammatory cytokine IL-6 and the chemokine IL-8,
in a time- and concentration-dependent fashion (Fig. 7 A),
demonstrating functionality of the IL-18 receptor ex-
pressed on vascular ECs and SMCs. Maximal activity re-
quired stimulation of either cell type with 15 ng recombi-
nant human IL-18/ml for 24 h. Higher concentrations (up
to 150 ng IL-18/ml, data not shown) or prolonged stimu-
lation (up to 48 h) did not increase IL-6 or IL-8 release
from ECs or SMCs.
To study additional proatherogenic functions triggered
by IL-18, we further tested whether stimulation with this
cytokine induced the expression of matrix metalloprotein-
ase (MMP), enzymes that likely render atheroma prone to
rupture and hence promote thrombosis. Indeed, IL-18 in-
duced the expression of MMP in all three cell types, as
demonstrated here for the interstitial collagenases MMP-1
and MMP-13 as well as the gelatinase MMP-9 in human
vascular SMC and MØ (Fig. 7 B). Although IL-18 as a
sole stimulus in several experiments induced both collage-
nases only weakly, combination with IL-12 enhanced the
expression to levels comparable to those obtained with
‘classical’ inducers of these MMP, such as IL-1  and
Figure 7. Expression of functional IL-18 receptor on cultured human
ECs, SMCs, and MØ. (A) Cultures of ECs or SMCs were stimulated
with recombinant human IL-18 (50 ng/ml) for the respective times (left)
or with the respective concentrations of IL-18 for 24 h (right). Culture
supernatants were analyzed by ELISA for IL-6 or IL-8. Data represent
mean   SD. Similar results were obtained in three independent experi-
ments. (B) Culture supernatants of SMCs or MØ stimulated with IL-1 /
TNF-  (10/50 ng/ml), IL-18 (50 ng/ml), IL-12 (10 ng/ml), or a combi-
nation of the latter two, were applied to Western blot analysis for MMP-1
or MMP-13, or to gelatin-zymography. Positions of the molecular weight
markers are indicated on the left. Comparable data were obtained using
cells from at least three different donors.253 Gerdes et al.
TNF- . Furthermore, IL-18 induced the expression of
ICAM-1 on ECs as determined by FACS® analysis (data
not shown).
IL-18 Induces IFN-  Production in MØ and Unexpectedly
by SMCs. We further investigated whether IL-18 also
mediates its originally recognized function, the induction
of IFN-  expression, on human vascular ECs and SMCs as
well as MØ. Indeed, IL-18, particularly in synergism with
IL-12, elicited IFN-  protein and transcript in MØ and,
even more surprisingly, in human vascular SMCs, a cell
type previously not implicated in the synthesis of this cy-
tokine, as shown by ELISA (Fig. 8 A), in situ hybridization,
and RT-PCR (Fig. 8 B). Of note, addition of Polymyxin
B did not diminish the expression of IFN-  transcripts or
protein, whereas heat inactivation of IL-12/IL-18 abol-
ished this function, excluding endotoxin contamination as
the cause of our observation (Fig. 8 A and B). Moreover,
other proinflammatory cytokines, such as IL-1  or TNF-
 , did not induce expression of IFN-  in these cell types.
The SMC cultures employed for these experiments ex-
pressed smooth muscle  -actin, however, did not yield a
signal for CD14 by RT-PCR or for CD3, CD4, CD31,
CD64, or CD68 by immunohistochemistry (data not
shown), suggesting that the passaged SMC cultures em-
ployed indeed contained negligible if any T lymphocytes,
ECs, or MØ. Of note, within the total of 15 different do-
nors, SMC cultures from five donors did not show induc-
tion of IFN-  (0.8   1.4 U IFN- /ml) compared with su-
pernatants of unstimulated cultures (1.4   1.8 U IFN- /
ml), even when maximal concentrations of IL-18 or IL-
12/IL-18 concentrations were applied. Within the group
of 10 experiments yielding significantly (P    0.05) en-
hanced IFN-  expression upon stimulation with IL-12/IL-
18 combination, low and high “responders” were identi-
fied. Five donors yielded an average of 16.5   12.9 U
IFN- /ml and the remaining five donors of 260   115 U
IFN- /ml. Although the cause remains unknown, neither
gender and age of the cell donor nor passage number of the
cells appeared to account for this observed variation. In
contrast to SMCs, MØ expressed IFN-  more uniformly
after stimulation with IL-12/IL-18 (220   43 U IFN- /
ml; n   4). EC did not express IFN-  in response to any of
the stimuli or combinations thereof tested, supporting the
cell type specificity of our finding (Fig. 8 A).
In view of the unexpected expression of IFN-  by
SMCs, we further tested the ability of medium condi-
tioned by IL-12/IL-18–stimulated SMCs to exhibit a
characteristic biological activity of IFN- . Indeed, incuba-
tion with culture supernatants derived from IL-12/IL-18-
stimulated SMCs enhanced the expression of MHC II in
EC (Fig. 8 C), compared to those cultured with superna-
tants of nontreated SMCs. Addition of neutralizing anti–
IFN-  antibody to the culture medium abrogated induc-
tion of MHC II on ECs, further validating the specificity
of our observations.
To demonstrate the potential relevance of the novel ob-
servation of IFN-  expression by SMCs to the pathogene-
sis of atherosclerosis, we performed in situ hybridization
studies on sections of human atheroma. In support of the in
vitro observations outlined above, IFN-  in atherosclerotic
lesions localized with T cells, but also within MØ- and
SMC-enriched areas, which were T cell deprived (Fig. 8
D). In contrast, nonatherosclerotic tissue did not contain
IFN-  mRNA. Moreover, application of sense oligomers
did not yield detectable signals. Unavailability of appropri-
ate antibodies hampered extension of these in situ results to
the protein level (see discussion).
Discussion
Recent research points to a prominent role of immunity
and inflammation in the pathogenesis of atherosclerosis (1–
3). Considerable data support the hypothesis that cytokines
orchestrate many of the complex processes underlying this
prevalent human disease (1–4, 6, 7, 42). The present study
highlights a novel potential pathway for signaling in
atherogenesis that involves the IL-18 receptor/ligand
dyad. It further reports the unexpected ability of vascular
SMCs to produce biologically active IFN-  after stimula-
tion with IL-18. Together, these findings considerably add
to the burgeoning evidence of a local, self-sustaining im-
mune, and inflammatory response within the atheroma-
tous plaque. Within the cytokine network, IFN-  has gar-
nered considerable interest as a regulator of atherogenesis.
Early studies implicated this cytokine in various proathero-
genic processes, including loss of fibrillar collagen and
modulation of inflammatory processes (27, 28, 43, 44). In-
deed, absence of IFN-  significantly diminishes formation
of atherosclerotic lesions in hypercholesterolemic mice.
Gupta et al. demonstrated that IFN-  promotes and modi-
fies atherosclerosis through both local effects in the arterial
wall, e.g., lesional lipid accumulation and enhanced col-
lagen content, as well as a systemic effect on plasma lipo-
proteins, concluding that therapeutic inhibition of IFN- 
signaling may lead to the formation of more lipid-depleted,
“stable” atheromata (4). Studies from our own and other
groups further demonstrated a causal role for IFN-  in
transplantation-associated arteriopathy (5, 45). Interest-
ingly, IFN-  can mediate atherosclerosis in the absence of
T lymphocytes, the classical source of this cytokine (6).
Our surprising finding that IL-18 induced the expression
of IFN-  not only in MØ, but also in vascular SMCs, a
previously unsuspected source, points to a novel potential
pathogenic pathway at play in both native and transplanta-
tion-associated atherosclerosis.
As mentioned above, unavailability of appropriate anti-
bodies hampered immunohistochemical analysis of IFN- 
expression in situ. Indeed, a very recent report has called
into question the specificity of various (13 different) anti–
IFN-  antibodies due to “cross-reactivity” with other cell
types than T lymphocytes, namely SMCs (46). Our
present findings would suggest a reevaluation of this con-
clusion, as some of the putatively spurious staining might
actually be genuine.254 IL-18/IL-18R in Human Atheroma255 Gerdes et al.
Our in situ findings indicate that MØ in human ather-
oma strongly express IL-18, a finding supported by a re-
port published after submission of this manuscript (47). In
contrast, nondiseased arterial tissue, which lacks MØ, did
not contain IL-18. The localization of the cytokine agrees
with previous reports, demonstrating IL-18 expression by
human MØ in vitro (14, 48). Inducers of IL-18 include
IL-1  and TNF- , proinflammatory cytokines expressed
in human atheroma, but not in nondiseased arteries (3,
44). Detection of the mature 18-kD form of IL-18 in pro-
tein extracts of human atheroma and cultured MØ sug-
gests the presence of the active form of the cytokine, a
finding in accordance with the expression of active cas-
pase-1 subunits. Although expression of IL-18 in atheroma
appears restricted to one cell type, several cells found in
atheroma express the IL-18 receptor, namely ECs, SMCs,
MØ, and T lymphocytes, as shown here and demonstrated
elsewhere (15, 16, 37, 47). Low level staining for IL-
18R  in nondiseased tissue, supported by Western blot
analysis, FACS®, and PCR data, suggested modest basal
expression of the receptor on vascular ECs, SMCs, and
MØ, a finding consistent with reports of constitutive ex-
pression of the IL-18 receptor on hematopoetic cell lines
(49). Interestingly, the combination of several cytokines
found in plaques, namely IL-1 , TNF- , and IFN- , pro-
moted the expression of both IL-18 receptor chains. Thus,
the enhanced expression of the IL-18 receptor in human
atheroma in situ corroborates the in vitro observations, in-
dicating the likelihood of IL-18 signaling in early and/or
advanced atherosclerotic lesions. In agreement, transfer of
an IL-18 binding protein plasmid into ApoE-deficient
mice diminishes atherosclerosis in vivo (50). The finding
that IFN-  alone did not enhance, but, when combined
with IL-1  and TNF- , did promote expression of the
IL-18 receptor, might reflect distinct pathways separating
physiologic from pathologic responses, since IL-1  and
TNF-  commonly coexist at sites of chronic inflammation
and are not required for physiologic T lymphocyte or NK
cell activation. Moreover, the inducibility of IL-18R / 
by IFN-  in an inflammatory setting combined with the
induction of IFN-  expression via IL-18 signaling suggests
a positive feedback loop in the vasculature, which might
contribute to the dysregulated inflammatory response
characterizing atheroma. Such a self-reinforcing IL-18/
IFN-  cascade could furthermore contribute to the domi-
nant Th1 response during atherogenesis (3). Notably, IL-
18 promotes Th1 immune responses via its well recog-
nized function to evoke IFN-  expression in lymphocytes
(14–16) as well as via IFN- –independent pathways,
probably in synergy with IL-12, although this function re-
mains controversial (20, 24, 25, 51). Accordingly, the Th1
lymphocyte subpopulation, but not Th2 lymphocytes, ex-
press the receptor for IL-18 (30). Our observations extend
the implications for the IL-18/IL-18R dyad in atheroscle-
rosis beyond regulation of IFN-  or Th1-mediated im-
mune responses. Ligation of the IL-18 receptor on ECs,
SMCs, MØ, and, as published previously, on T lympho-
cytes, induced expression of cytokines and chemokines,
such as IL-6, IL-8, and as shown by others, of IL-1  and
TNF- , molecules implicated in atherogenesis (1, 2, 16).
Moreover, IL-18 induced the expression of adhesion mol-
ecules and at least two classes of matrix degrading en-
zymes, including interstitial collagenases, enzymes consid-
ered crucial for the degradation of fibrillar collagen, the
major load-bearing molecule of the atheroma’s fibrous cap
(38). Thus, IL-18 signaling probably promotes processes
underlying weakening of the plaque’s extracellular matrix,
rendering lesions prone to rupture, the proximate cause of
most coronary thromboses. In addition, IL-18 might con-
tribute to atherogenesis in other ways, for example pro-
moting production of proinflammatory cytokines and
adhesion molecules, as well as growth factors (e.g., GM-
CSF), inducible nitric oxide synthase, or inducible cy-
clooxygenase (15, 16, 18, 20, 21, 24). Aside from mediat-
ing proatherogenic functions directly, IL-18 might further
augment atherogenesis by inhibiting TGF-  function (18),
a pathway that may mitigate this disease (52). In conclu-
sion, our data identify a novel step proximal to IFN-  in
the inflammatory pathways of atherosclerosis. We have
uncovered a new source of IFN-  in atheroma, a finding
that should stimulate the evaluation of SMC-derived IFN- 
in other chronic inflammatory diseases and in vasculitides.
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Figure 8. IL-18 induces expression of IFN-  on vascular SMCs and MØ. (A) Cultures of SMCs or ECs were stimulated (36 h) with either IL-1 /
TNF-  (10/50 ng/ml), IL-12 (10 ng/ml), respective concentrations of IL-18, or combinations of the latter two, and supernatants were analyzed by
ELISA for IFN- . Polymyxin B and heat treated IL-12/IL-18 (95 C for 10 min) were applied to exclude activation via endotoxin contamination. Data
represent mean   SD. Similar results were obtained in at least three independent experiments. (B, right) Total RNA obtained from cultured SMCs stim-
ulated with medium alone (None), IL-12, IL-18, or combinations thereof, was analyzed by RT-PCR for IFN-  transcripts. (B, left) MØ or SMCs cul-
tured to confluence on 4-well chamber slides were analyzed for the expression of IFN-  transcripts by in situ hybridization using the respective antisense
or sense oligomers. (C) Supernatants of SMC cultures stimulated with medium alone (SMC-SN, none) or combination of IL-12 (10 ng/ml) and IL-18
(50 ng/ml) (SMC-SN (IL-12/18)) were applied in absence or presence of neutralizing  -IFN-  antibody (SMC-SN (IL-12/18)    -IFN- ) to conflu-
ent EC cultures for 48 h and MHC II expression was compared with unstimulated (none) or IFN- –stimulated (rIFN- , 1,000 U/ml) ECs by FACS®
analysis. Staining (solid histograms) was compared with isotype control (dotted line). At least 20,000 viable cells were analyzed for each staining. Values of
geometric mean fluorescence are indicated in each panel. Similar results were obtained in three independent experiments using cells of different individ-
uals. (D, left) Serial cryostat sections of frozen specimens of carotid atheroma were analyzed for the expression of IFN-  transcripts by in situ hybridiza-
tion using the respective antisense (top) or sense (bottom) oligomers. Low (original magnification: 4 , left) and high (original magnification: 40 , right)
magnifications are shown. The asterisks indicate the lumen of the vessels. (D, right) Adjacent sections were stained for SMCs (anti– -actin), MØ
(anti-CD68), or T lymphocytes (anti-CD3). Low (4 ) and high (40 , insets) magnifications are shown.256 IL-18/IL-18R in Human Atheroma
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